Answer Questions about Andexxa, the New Apixaban and Rivaroxaban Reversal Agent

July 2018

You'll hear about Andexxa (an-DEK-sah, inactivated recombinant factor Xa), the new, IV direct oral anticoagulant (DOAC) reversal agent.

Andexxa binds and inactivates factor Xa inhibitors...compared to idarucizumab (Praxbind), which reverses dabigatran (Pradaxa).

Andexxa's FDA approval is based on quick reversal of clotting time in patients taking apixaban and rivaroxaban. But it's also being studied with other anticoagulants...betrixaban (Bevyxxa), edoxaban (Savaysa), and enoxaparin.

Get concise advice on drug therapy, plus unlimited access to CE

Hospital Pharmacist's Letter includes:

12 issues every year, with brief articles about new meds and hot topics
200+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Anticoagulants Answer Questions about Andexxa, the New Apixaban and Rivaroxaban Reversal Agent
Liver Disease Ensure Patients With Acute Variceal Bleeding Get Appropriate Treatment
Stroke Update Acute Stroke Protocols With the Latest Evidence
Transitions of Care Safely Transition Patients Taking Investigational Drugs at Home
Anesthesia Be Ready to Treat Toxicity From Local Anesthetics With IV Lipids
Practice Help Relieve Shortages by Expanding IV-to-PO Switches
Crohn's Disease Optimize Crohn's Maintenance Therapy During Hospitalization
New Drugs Substitute Xhance for Your Hospital's Intranasal Steroid
Infectious Diseases Watch for Acute Infections in Patients on Chronic Antibiotics
Aspirin Put the Aspirin and NSAID Interaction in Perspective

Answer Questions about Andexxa, the New Apixaban and Rivaroxaban Reversal Agent

Get concise advice on drug therapy, plus unlimited access to CE

Table of Contents